UPDATE: Burrill Initiates Sangamo Biosciences at Market Outperform
Burrill initiated coverage on Sangamo Biosciences (NASDAQ: SGMO) with a Market Outperform rating and a $28.00 price target.
Burrill noted, "We believe Sangamo's innovative genome editing approach could provide novel and transformative therapeutics, which could revolutionize the treatment of genetic disorders. … We believe there is a significant upside to our valuation, given the additional opportunities embedded in the platform, not to mention ex-U.S. markets, which aren't included in our calculation."
Sangamo Biosciences closed at $8.82 on Friday.
(c) 2013 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.